文献速递冠心病血脂与心血管预防

LPA KIV-2 常见变异降低脂蛋白(a)并预防冠心病

Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

本研究在 GCKD 研究(n=4,673)中对 LPA KIV-2 区剪接变异 4733G>A 进行基因分型,并通过 UK Biobank(n=440,234)分析其与冠心病的关系。结果显示该变异携带频率 38.2%,降低 Lp(a) 13.6 mg/dL,并与 4925G>A 复合杂合降低 Lp(a) 31.8 mg/dL,分别降低冠心病风险 9% 和 12%。

要点

  • LPA KIV-2 4733G>A 携带频率 38.2%,降低 Lp(a) 13.6 mg/dL。
  • 与 4925G>A 复合杂合降低 Lp(a) 31.8 mg/dL,冠心病风险降 12%。
  • 终生中度 Lp(a) 降低即可带来明显冠心病风险下降。

核心结论

  • LPA KIV-2 区功能变异共同决定 Lp(a) 水平和冠心病风险,终生中度 Lp(a) 降低可显著降低冠心病风险。

研究设计与样本

  • 在 GCKD 研究(n=4,673)中对 4733G>A 进行等位基因特异性 PCR 基因分型,并进行小基因剪接试验。
  • 利用代理单核苷酸多态性在 UK Biobank(n=440,234)中通过生存分析评估冠心病风险。
  • 在 1000 Genomes Project 中评估不同种族频率。

主要发现

  • 4733G>A 携带频率 38.2%,存在于大多数异构体大小中,降低等位基因表达但不完全消除蛋白产生。
  • 4733G>A 降低 Lp(a) 13.6 mg/dL(95% CI: 12.5-14.7; P < 0.0001),是仅次于较小异构体的最强变异解释因素。
  • 4733G>A 与 4925G>A 复合杂合(人群 4.6%)降低 Lp(a) 31.8 mg/dL,并将四分位距缩小 9 倍(从 42.1 降至 4.6 mg/dL)。
  • 在 UK Biobank 中,4733G>A 单独及与 4925G>A 复合杂合分别降低冠心病 HR 9%(95% CI: 7%-11%)和 12%(95% CI: 7%-16%)(均 P < 0.001)。
  • 不同种族间频率差异显著。

关键数值与推荐

  • 4733G>A 携带频率 38.2%,降低 Lp(a) 13.6 mg/dL(95% CI: 12.5-14.7; P < 0.0001)。
  • 复合杂合(4.6% 人群)降低 Lp(a) 31.8 mg/dL,四分位距从 42.1 降至 4.6 mg/dL。
  • 4733G>A 降低冠心病 HR 9%(95% CI: 7%-11%),复合杂合降低 12%(95% CI: 7%-16%)(均 P < 0.001)。

临床怎么用

  • LPA KIV-2 区变异检测有助于解释 Lp(a) 水平变异和冠心病风险。
  • 终生中度 Lp(a) 降低可转化为明显的冠心病风险下降,支持 Lp(a) 作为干预靶点。

局限性

  • 研究主要基于欧洲人群,种族频率差异显著,外推需谨慎。
  • KIV-2 区传统技术难以覆盖,依赖代理 SNP 和基因分型方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lipoprotein(a) (Lp(a)) concentrations are a major independent risk factor for coronary artery disease (CAD) and are mainly determined by variation in LPA. Up to 70% of the LPA coding sequence is located in the hypervariable kringle IV type 2 (KIV-2) region. It is hardly accessible by conventional technologies, but may contain functional variants. OBJECTIVES: This study sought to investigate the new, very frequent splicing variant KIV-2 4733G>A on Lp(a) and CAD. METHODS: We genotyped 4733G>A in the GCKD (German Chronic Kidney Disease) study (n = 4,673) by allele-specific polymerase chain reaction, performed minigene assays, identified proxy single nucleotide polymorphisms and used them to characterize its effect on CAD by survival analysis in UK Biobank (n = 440,234). Frequencies in ethnic groups were assessed in the 1000 Genomes Project. RESULTS: The 4733G>A variant (38.2% carrier frequency) was found in most isoform sizes. It reduces allelic expression without abolishing protein production, lowers Lp(a) by 13.6 mg/dL (95% CI: 12.5-14.7; P < 0.0001) and is the strongest variance-explaining factor after the smaller isoform. Splicing of minigenes was modified. Compound heterozygosity (4.6% of the population) for 4733G>A and 4925G>A, another KIV-2 splicing mutation, reduces Lp(a) by 31.8 mg/dL and most importantly narrows the interquartile range by 9-fold (from 42.1 to 4.6 mg/dL) when compared to the wild type. In UK Biobank 4733G>A alone and compound heterozygosity with 4925G>A reduced HR for CAD by 9% (95% CI: 7%-11%) and 12% (95% CI: 7%-16%) (both P < 0.001). Frequencies in ethnicities differ notably. CONCLUSIONS: Functional variants in the previously inaccessible LPA KIV-2 region cooperate in determining Lp(a) variance and CAD risk. Even a moderate but lifelong genetic Lp(a) reduction translates to a noticeable CAD risk reduction.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Schachtl-Riess JF, Kheirkhah A, Grüneis R, et al. Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease. J Am Coll Cardiol. 2021. PMID: 34325833. doi:10.1016/j.jacc.2021.05.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。